MTOR and cancer: Ultimately, our findings may provide a novel strategy for patients with HPV− HNSCC by cotargeting mTOR and key cell cycle–regulating molecules, which can also have an impact in multiple cancer types that fail to respond to CDK4/6 inhibitors as single agents.